Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 6 | 2018 | 486 | 1.020 |
Why?
|
| HIV-1 | 6 | 2018 | 755 | 0.900 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 67 | 0.900 |
Why?
|
| HIV Infections | 18 | 2015 | 2586 | 0.860 |
Why?
|
| Puerto Rico | 28 | 2017 | 1413 | 0.800 |
Why?
|
| Substance Abuse, Intravenous | 6 | 2009 | 129 | 0.800 |
Why?
|
| Hepatitis C | 4 | 2006 | 139 | 0.670 |
Why?
|
| Proteoglycans | 1 | 2018 | 49 | 0.560 |
Why?
|
| Viral Load | 3 | 2015 | 348 | 0.550 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 65 | 0.550 |
Why?
|
| Curcumin | 2 | 2015 | 118 | 0.510 |
Why?
|
| Virus Replication | 1 | 2018 | 318 | 0.480 |
Why?
|
| Viremia | 1 | 2015 | 44 | 0.470 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2011 | 226 | 0.460 |
Why?
|
| Anti-Retroviral Agents | 2 | 2015 | 160 | 0.450 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2018 | 247 | 0.430 |
Why?
|
| Mutation | 4 | 2017 | 1177 | 0.430 |
Why?
|
| Fatty Acids | 1 | 2015 | 134 | 0.420 |
Why?
|
| Science | 1 | 2013 | 24 | 0.400 |
Why?
|
| Career Choice | 1 | 2013 | 52 | 0.400 |
Why?
|
| Cytokines | 4 | 2015 | 678 | 0.370 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 12 | 0.320 |
Why?
|
| Humans | 38 | 2018 | 43102 | 0.310 |
Why?
|
| Equipment Reuse | 1 | 2009 | 3 | 0.300 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2011 | 229 | 0.300 |
Why?
|
| Drug Tolerance | 2 | 2008 | 26 | 0.290 |
Why?
|
| Drug Users | 1 | 2009 | 52 | 0.290 |
Why?
|
| Drug Compounding | 1 | 2009 | 93 | 0.280 |
Why?
|
| Female | 30 | 2017 | 24698 | 0.280 |
Why?
|
| Methadone | 1 | 2008 | 24 | 0.280 |
Why?
|
| Narcotics | 1 | 2008 | 29 | 0.280 |
Why?
|
| Male | 29 | 2017 | 23409 | 0.280 |
Why?
|
| Adult | 23 | 2015 | 13872 | 0.270 |
Why?
|
| Th2 Cells | 2 | 2006 | 62 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2010 | 989 | 0.270 |
Why?
|
| Morphine | 1 | 2008 | 69 | 0.270 |
Why?
|
| Heroin Dependence | 1 | 2006 | 23 | 0.250 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 16 | 0.250 |
Why?
|
| Risk-Taking | 4 | 2015 | 457 | 0.250 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1019 | 0.250 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 41 | 0.250 |
Why?
|
| Cocaine-Related Disorders | 1 | 2006 | 102 | 0.240 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 33 | 0.230 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2015 | 34 | 0.220 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2004 | 279 | 0.220 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 203 | 0.220 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 6 | 0.210 |
Why?
|
| Cardiac Tamponade | 1 | 2004 | 6 | 0.210 |
Why?
|
| Dermatomyositis | 1 | 2004 | 9 | 0.210 |
Why?
|
| Macrophages | 1 | 2008 | 529 | 0.200 |
Why?
|
| Middle Aged | 14 | 2015 | 12222 | 0.200 |
Why?
|
| HIV | 2 | 2006 | 100 | 0.200 |
Why?
|
| Hepacivirus | 2 | 2006 | 74 | 0.190 |
Why?
|
| Cells, Cultured | 4 | 2018 | 1621 | 0.180 |
Why?
|
| Adolescent | 12 | 2015 | 6081 | 0.180 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 1234 | 0.180 |
Why?
|
| Prevalence | 6 | 2010 | 1612 | 0.170 |
Why?
|
| Cross-Sectional Studies | 8 | 2014 | 3156 | 0.170 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2013 | 201 | 0.170 |
Why?
|
| T-Lymphocytes | 2 | 2002 | 386 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2015 | 1759 | 0.150 |
Why?
|
| Sex Factors | 3 | 2015 | 1028 | 0.150 |
Why?
|
| Immunologic Factors | 2 | 2015 | 51 | 0.140 |
Why?
|
| Time Factors | 3 | 2015 | 1857 | 0.140 |
Why?
|
| Chemokines | 1 | 2018 | 96 | 0.130 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2015 | 67 | 0.130 |
Why?
|
| Age Factors | 2 | 2015 | 1154 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2015 | 760 | 0.130 |
Why?
|
| Adolescent Behavior | 3 | 2015 | 281 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 4 | 2015 | 117 | 0.120 |
Why?
|
| DNA, Superhelical | 1 | 2015 | 7 | 0.120 |
Why?
|
| Alkynes | 1 | 2015 | 52 | 0.120 |
Why?
|
| Smallpox | 1 | 2015 | 1 | 0.120 |
Why?
|
| Variola virus | 1 | 2015 | 1 | 0.120 |
Why?
|
| Smallpox Vaccine | 1 | 2015 | 2 | 0.120 |
Why?
|
| Stomatitis | 1 | 2014 | 2 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 2853 | 0.110 |
Why?
|
| School Health Services | 1 | 2015 | 90 | 0.110 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 31 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 432 | 0.110 |
Why?
|
| Mouth | 1 | 2014 | 54 | 0.110 |
Why?
|
| Risk Factors | 5 | 2015 | 3994 | 0.100 |
Why?
|
| Drug Resistance, Multiple | 1 | 2013 | 28 | 0.100 |
Why?
|
| Gram-Positive Bacteria | 1 | 2013 | 21 | 0.100 |
Why?
|
| Gram-Negative Bacteria | 1 | 2013 | 29 | 0.100 |
Why?
|
| Young Adult | 3 | 2015 | 5080 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2013 | 50 | 0.100 |
Why?
|
| Substance-Related Disorders | 2 | 2014 | 830 | 0.100 |
Why?
|
| Carcinoma, Ehrlich Tumor | 2 | 1989 | 20 | 0.090 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2011 | 9 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 44 | 0.090 |
Why?
|
| Aged | 4 | 2015 | 8214 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 236 | 0.080 |
Why?
|
| Unfolded Protein Response | 1 | 2010 | 22 | 0.080 |
Why?
|
| Raynaud Disease | 1 | 2010 | 8 | 0.080 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 14 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 376 | 0.080 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 108 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 61 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2010 | 132 | 0.080 |
Why?
|
| Cimetidine | 1 | 1989 | 1 | 0.080 |
Why?
|
| Cyclosporins | 1 | 1989 | 2 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 925 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 161 | 0.080 |
Why?
|
| Syringes | 1 | 2009 | 7 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2010 | 63 | 0.070 |
Why?
|
| Diffusion of Innovation | 1 | 2009 | 38 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2010 | 172 | 0.070 |
Why?
|
| Interleukin-2 | 1 | 1989 | 91 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2015 | 1600 | 0.070 |
Why?
|
| Naloxone | 1 | 2008 | 56 | 0.070 |
Why?
|
| Minority Groups | 1 | 2013 | 690 | 0.070 |
Why?
|
| Ethanol | 1 | 2010 | 224 | 0.070 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 78 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 95 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2676 | 0.070 |
Why?
|
| Students | 1 | 2013 | 626 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2009 | 359 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 2 | 1998 | 109 | 0.070 |
Why?
|
| Apoptosis | 1 | 2015 | 1568 | 0.070 |
Why?
|
| Chemokine CCL3 | 1 | 2006 | 14 | 0.060 |
Why?
|
| Chemokine CCL4 | 1 | 2006 | 19 | 0.060 |
Why?
|
| Genotype | 2 | 2017 | 800 | 0.060 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2008 | 126 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2006 | 41 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2006 | 74 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2006 | 97 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 575 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2006 | 458 | 0.060 |
Why?
|
| Mortality | 2 | 2005 | 175 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2006 | 883 | 0.060 |
Why?
|
| CD4-CD8 Ratio | 2 | 2002 | 29 | 0.060 |
Why?
|
| Community-Based Participatory Research | 1 | 2009 | 352 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1124 | 0.060 |
Why?
|
| Health Care Reform | 1 | 2005 | 36 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2008 | 638 | 0.050 |
Why?
|
| Hospitals | 1 | 2005 | 117 | 0.050 |
Why?
|
| Prednisone | 1 | 2004 | 31 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2004 | 17 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2005 | 246 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 67 | 0.050 |
Why?
|
| Comorbidity | 3 | 2014 | 737 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2004 | 260 | 0.050 |
Why?
|
| Pneumonia | 1 | 2003 | 61 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2002 | 17 | 0.050 |
Why?
|
| Infant | 2 | 2005 | 1175 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 1063 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2002 | 64 | 0.050 |
Why?
|
| Social Class | 1 | 2005 | 291 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2005 | 972 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2005 | 1546 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 187 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 184 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2002 | 411 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2001 | 206 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1455 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2001 | 321 | 0.040 |
Why?
|
| Disease Progression | 1 | 2002 | 667 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2004 | 1604 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 20 | 0.040 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1998 | 22 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 1998 | 35 | 0.040 |
Why?
|
| Child | 2 | 2005 | 3443 | 0.040 |
Why?
|
| Plants, Medicinal | 1 | 1998 | 57 | 0.030 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 29 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 1998 | 144 | 0.030 |
Why?
|
| HIV Protease | 1 | 2017 | 23 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2013 | 245 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1997 | 94 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 249 | 0.030 |
Why?
|
| Neoplasms | 1 | 2008 | 1377 | 0.030 |
Why?
|
| DNA Gyrase | 1 | 2015 | 8 | 0.030 |
Why?
|
| Vero Cells | 1 | 2015 | 112 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2015 | 16 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2015 | 32 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1998 | 302 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2015 | 48 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 2015 | 80 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 29 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 74 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 64 | 0.030 |
Why?
|
| Mice | 4 | 2015 | 6644 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 94 | 0.030 |
Why?
|
| Animals | 5 | 2015 | 16992 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2014 | 196 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2014 | 311 | 0.020 |
Why?
|
| Prisoners | 1 | 2014 | 102 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 306 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2015 | 460 | 0.020 |
Why?
|
| Alcoholism | 1 | 2014 | 305 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 32 | 0.020 |
Why?
|
| HTLV-I Antibodies | 1 | 1989 | 7 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2014 | 638 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 233 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 1596 | 0.020 |
Why?
|
| Proteome | 1 | 2010 | 152 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 1989 | 104 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 518 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2014 | 661 | 0.020 |
Why?
|
| Gene Expression | 1 | 2010 | 701 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 1989 | 1869 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 368 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 420 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 539 | 0.010 |
Why?
|
| Pneumococcal Vaccines | 1 | 2003 | 16 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 152 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2010 | 719 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 835 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1078 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1998 | 21 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1998 | 46 | 0.010 |
Why?
|
| Artemia | 1 | 1998 | 13 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1998 | 68 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1998 | 60 | 0.010 |
Why?
|
| Mycobacterium | 1 | 1998 | 16 | 0.010 |
Why?
|
| Biological Assay | 1 | 1998 | 63 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1998 | 127 | 0.010 |
Why?
|
| Influenza Vaccines | 1 | 1997 | 58 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 1997 | 129 | 0.010 |
Why?
|
| HTLV-I Infections | 1 | 1989 | 33 | 0.000 |
Why?
|
| Genes, Viral | 1 | 1989 | 61 | 0.000 |
Why?
|